Synthesis, Characterization, and Interaction with Biomolecules of Platinum(II) Complexes with Shikimic Acid-Based Ligands

Starting from the active ingredient shikimic acid (SA) of traditional Chinese medicine and NH2(CH2)nOH, (n = 2–6), we have synthesized a series of new water-soluble Pt(II) complexes PtLa–eCl2, where La–e are chelating diamine ligands with carbon chain covalently attached to SA (La–e = SA-NH(CH2)nNHCH2CH2NH2; La, n = 2; Lb, n = 3; Lc, n = 4; Ld, n = 5; Le, n = 6). The results of the elemental analysis, LC-MS, capillary electrophoresis, and 1H, 13C NMR indicated that there was only one product (isomer) formed under the present experimental conditions, in which the coordinate mode of PtLa–eCl2 was two-amine bidentate. Their in vitro cytotoxic activities were evaluated by MTT method, where these compounds only exhibited low cytotoxicity towards BEL7404, which should correlate their low lipophilicity. The interactions of the five Pt(II) complexes with DNA were investigated by agarose gel electrophoresis, which suggests that the Pt(II) complexes could induce DNA alteration. We also studied the interactions of the Pt(II) complexes with 5′-GMP with ESI-MS and 1H NMR and found that PtLbCl2, PtLcCl2, and PtLdCl2 could react with 5′-GMP to form mono-GMP and bis-GMP adducts. Furthermore, the cell-cycle analysis revealed that PtLbCl2, PtLcCl2 cause cell G2-phase arrest after incubation for 72 h. Overall, these water-soluble Pt(II) complexes interact with DNA mainly through covalent binding, which blocks the DNA synthesis and replication and thus induces cytotoxicity that weakens as the length of carbon chain increases.

[1]  T. Mueller,et al.  Lipophilic Pt(II) complexes with selective efficacy against cisplatin-resistant testicular cancer cells. , 2011, Journal of inorganic biochemistry.

[2]  M. Jakupec,et al.  Synthesis and characterization of novel bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes with higher cytotoxicity than cisplatin , 2011, European journal of medicinal chemistry.

[3]  I. Santos,et al.  Pt(II) complexes with bidentate and tridentate pyrazolyl-containing chelators: synthesis, structural characterization and biological studies. , 2011, Dalton transactions.

[4]  U. Jaehde,et al.  Enhancing lipophilicity as a strategy to overcome resistance against platinum complexes? , 2011, Journal of inorganic biochemistry.

[5]  V. Rodríguez,et al.  Novel C,N-chelate platinum(II) antitumor complexes bearing a lipophilic ethisterone pendant. , 2011, Journal of inorganic biochemistry.

[6]  J. Platts,et al.  Molecular and statistical modeling of reduction peak potential and lipophilicity of platinum(IV) complexes , 2011, JBIC Journal of Biological Inorganic Chemistry.

[7]  Hong Liang,et al.  High cytotoxicity of dihalo-substituted 8-quinolinolato-lanthanides. , 2011, Dalton transactions.

[8]  D. N'Da,et al.  Water-Soluble Macromolecular Platinum Conjugates Derived from 1,2-Dihydroxyl-Functionalized Carrier Polymers , 2010 .

[9]  A. Chaudhuri,et al.  Cationic amphiphile with shikimic acid headgroup shows more systemic promise than its mannosyl analogue as DNA vaccine carrier in dendritic cell based genetic immunization. , 2010, Journal of Medicinal Chemistry.

[10]  D. Migoni,et al.  Water‐soluble Organometallic Analogues of Oxaliplatin with Cytotoxic and Anticlonogenic Activity , 2010, ChemMedChem.

[11]  A. Spek,et al.  Mono- and dinuclear platinum(II) compounds with 5,7-dimethyl-1,2,4-triazolo[1,5-a]pyrimidine. Structure, cytotoxic activity and reaction with 5'-GMP. , 2009, Dalton transactions.

[12]  M. Schürmann,et al.  On the many roles of NH3 ligands in mono- and multinuclear complexes of platinum. , 2009, Dalton transactions.

[13]  D. Gibson The mechanism of action of platinum anticancer agents--what do we really know about it? , 2009, Dalton transactions.

[14]  D. Osella,et al.  The drug targeting and delivery approach applied to pt-antitumour complexes. A coordination point of view. , 2009, Current medicinal chemistry.

[15]  U. Häfeli,et al.  Long-chain rhenium and technetium glucosamine conjugates. , 2009, Dalton transactions.

[16]  Katherine S. Lovejoy,et al.  Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting. , 2009, Dalton transactions.

[17]  F. Zunino,et al.  Strategies to improve the efficacy of platinum compounds. , 2009, Current medicinal chemistry.

[18]  Yi-zhi Li,et al.  Binuclear monofunctional platinum(II) complexes formed by hexaazamacrocyclic bisdien ligands: Crystal structure, DNA binding and cytotoxicity studies , 2009 .

[19]  R. Schibli,et al.  Novel glycated [99mTc(CO)3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors. , 2008, Bioconjugate chemistry.

[20]  B. Keppler,et al.  Carbohydrate-metal complexes and their potential as anticancer agents. , 2008, Current medicinal chemistry.

[21]  Katherine S. Lovejoy,et al.  cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects , 2008, Proceedings of the National Academy of Sciences.

[22]  K. Geckeler,et al.  Supramolecular nanoencapsulation as a tool: solubilization of the anticancer drug trans-dichloro(dipyridine)platinum(II) by complexation with beta-cyclodextrin. , 2008, Molecular pharmaceutics.

[23]  F. Schmidtchen,et al.  A novel synthesis of chiral guanidinium receptors and their use in unfolding the energetics of enantiorecognition of chiral carboxylates. , 2008, The Journal of organic chemistry.

[24]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[25]  M. Hall,et al.  Basis for design and development of platinum(IV) anticancer complexes. , 2007, Journal of medicinal chemistry.

[26]  Stephen J Lippard,et al.  Direct cellular responses to platinum-induced DNA damage. , 2007, Chemical reviews.

[27]  A. Beck‐Sickinger,et al.  New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumors. , 2007, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[28]  J. Schellens,et al.  Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients , 2007, Cancer Chemotherapy and Pharmacology.

[29]  M. Dolan,et al.  Molecular mechanisms of resistance and toxicity associated with platinating agents. , 2007, Cancer treatment reviews.

[30]  Veronique Maes,et al.  Novel 99mTc-labeled neurotensin analogues with optimized biodistribution properties. , 2006, Journal of medicinal chemistry.

[31]  Dik‐Lung Ma,et al.  Water soluble luminescent platinum terpyridine complexes with glycosylated acetylide and arylacetylide ligands: photoluminescent properties and cytotoxicities. , 2005, Chemical communications.

[32]  Mark T. Johnson,et al.  A Water-Soluble Polyamide Containing cis-dicarboxylato-chelated Platinum(II) , 2005 .

[33]  L. Collette,et al.  Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer , 2005, Oncology.

[34]  R. Knuechel,et al.  Distribution and subcellular localization of a water-soluble hematoporphyrin-platinum(II) complex in human bladder cancer cells. , 2004, Cancer letters.

[35]  F. Avilés,et al.  Water-soluble platinum(II) complexes of diamine chelating ligands bearing amino-acid type substituents: the effect of the linked amino acid and the diamine chelate ring size on antitumor activity, and interactions with 5'-GMP and DNA. , 2004, Journal of inorganic biochemistry.

[36]  E. Framery,et al.  Palladium-catalyzed asymmetric allylic alkylation using chiral glucosamine-based monophosphines , 2003 .

[37]  P. Wang,et al.  Expeditious syntheses of two carbohydrate-linked cisplatin analogs. , 2002, Carbohydrate research.

[38]  Y. Sohn,et al.  Synthesis and selective tumor targeting properties of water soluble porphyrin-Pt(II) conjugates. , 2002, Journal of inorganic biochemistry.

[39]  W. Zimmermann,et al.  (Aminoethanol)dichloroplatinum(II) complexes: influence of the hydroxyethyl moiety on 5'-GMP and DNA binding, intramolecular stability, the partition coefficient and anticancer activity. , 2002, Journal of inorganic biochemistry.

[40]  T. Okamoto,et al.  Unprecedented sugar-dependent in vivo antitumor activity of carbohydrate-pendant cis-diamminedichloroplatinum(II) complexes. , 2001, Bioorganic & medicinal chemistry letters.

[41]  W. Denny,et al.  cis-Dichloroplatinum(II) complexes tethered to 9-aminoacridine-4-carboxamides: synthesis and action in resistant cell lines in vitro. , 2001, Journal of inorganic biochemistry.

[42]  E. T. Cesar,et al.  Synthesis of Platinum Complexes from Sugar Derivatives , 2000 .

[43]  J. Reedijk Why does Cisplatin reach Guanine-n7 with competing s-donor ligands available in the cell? , 1999, Chemical reviews.

[44]  C. Giandomenico,et al.  Current status of platinum-based antitumor drugs. , 1999, Chemical reviews.

[45]  S. Lippard,et al.  Structure, Recognition, and Processing of Cisplatin-DNA Adducts. , 1999, Chemical reviews.

[46]  P. Wang,et al.  A Carbohydrate-Linked Cisplatin Analogue Having Antitumor Activity. , 1999, Angewandte Chemie.

[47]  D. Lebwohl,et al.  Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. , 1998, European journal of cancer.

[48]  A. Spatola,et al.  Mechanism of Palladium-Catalyzed Transfer Hydrogenolysis of Aryl Chlorides by Formate Salts , 1995 .

[49]  J. Kozelka,et al.  Effect of platinum N7-binding to deoxyguanosine and deoxyadenosine on the H8 and H2 chemical shifts. A quantitative analysis , 1994 .

[50]  Y. Kitano,et al.  Synthesis, structure and antitumor activity of a new water-soluble platinum complex, (1R,2R-cyclohexanediamine-N,N')[2-hydroxy-4-oxo-2-pentenoato(2-)-O2] platinum(II). , 1993, Chemical & pharmaceutical bulletin.

[51]  W. Denny,et al.  DNA-directed alkylating agents. 5. Acridinecarboxamide derivatives of (1,2-diaminoethane)dichloroplatinum(II). , 1992, Journal of medicinal chemistry.

[52]  Y. Kitano,et al.  Synthesis, Structure and Antitumor of a Water-Soluble Platinum Complex, (1R, 3R, 4R, 5R)-(-)-Quinato(1R, 2R-cyclohexanediamine)platinum(II) , 1992 .

[53]  N. Farrell,et al.  Shikimic acid complexes of platinum. Preparation, reactivity, and antitumor activity of (R,R-1,2-diaminocyclohexane) bis(shikimato) platinum(II). Evidence for a novel rearrangement involving platinum-carbon bond formation. , 1991, Journal of inorganic biochemistry.

[54]  F. Zunino,et al.  New Cisplatin Analogues—On the Way to Better Antitumor Agents , 1987 .

[55]  L. Marzilli,et al.  Interaction of platinum antitumor agents with guanine nucleosides and nucleotides. Platinum-195 and proton NMR spectroscopic characterization of compound III , 1985 .

[56]  P. Lohman,et al.  Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. , 1985, Biochemistry.

[57]  A. Marcelis,et al.  Reaction products of cis-diammineplatinum(II) compounds with 5'-guanosine monophosphate characterized by high-frequency proton NMR , 1984 .

[58]  H. C. Clark,et al.  Preparation and characterization of platinum(II) complexes Pt(P-C)LX, where (P-C) is metalated tri-tert-butylphosphine , 1980 .

[59]  J. Trosko,et al.  Platinum Compounds: a New Class of Potent Antitumour Agents , 1969, Nature.

[60]  Valeria Panebianco,et al.  Supplementary Figure 2 , 2012 .

[61]  M. Jakupec,et al.  Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes. , 2011, Journal of inorganic biochemistry.

[62]  Igor V Tetko,et al.  Calculation of lipophilicity for Pt(II) complexes: experimental comparison of several methods , 2008, Journal of inorganic biochemistry.

[63]  P. Pochet A Quantitative Analysis , 2006 .

[64]  Sun Li-min Application of ammonium formate in catalytic transfer hydrogenation , 2005 .

[65]  R. Weiss,et al.  New Cisplatin Analogues in Development A Review , 2022 .